ERC Starting Grant · 2025
Innovative CAR immune cell communities to break solid tumor barriers
Glioblastoma is the most common and most aggressive primary brain tumor in adults. It is paradigmatic for many incurable, poorly immunologic solid tumors that desperately need more effective therapies. Cellular immunotherapies with engineered immune cells expressing synthetic chimeric antigen receptors (CAR) to recognize cancer cells have great therapeutic potential. However, significant barriers related to cell manufacturing, immune cell migration and activation in the tumor environment and failure to engage the host immune system, have hindered the breakthrough of CAR cell therapies against solid tumors like glioblastoma. Our recent research shows encouraging results by combining…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.